Agentix Corp. (AGTX)

Market Cap	801.34K -59.0%
Revenue (ttm)	n/a
Net Income	-417.49K
EPS	-0.01
Shares Out	40.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.0200
Previous Close	n/a
Day's Range	0.0200 - 0.0200
52-Week Range	0.0142 - 0.0550
Beta	1.08
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Agentix

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National H...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: AGTX

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 20, 2026

Data Sources Report a data error